ALLMedicine™ Alpha1-antitrypsin Deficiency Center

Oct 28th, 2021 - This study is a multicenter, open-label trial to evaluate the safety and pharmacokinetics of weekly intravenous (IV) infusions of 60 mg/kg of the investigational drug in participants with alpha1-antitrypsin deficiency (AATD). The trial will be con...

Jul 14th, 2021 - Alpha1-antitrypsin deficiency (AATD) is caused by mutations in the SERPINA1 gene, coding for alpha1-antitrypsin (AAT). AAT is synthesised mainly in the liver and is released into bloodstream to protect tissues (particularly lung) with its antiprot...

May 20th, 2021 - Alpha1-antitrypsin deficiency arises due to mutations in alpha1-antitrypsin (AAT) gene and represents the most prominent genetic predisposition to chronic obstructive pulmonary disease and emphysema. Since AAT plays important immunomodulatory and ...

Mar 24th, 2021 - A better understanding is needed of the different phenotypes that exist for patients with chronic obstructive pulmonary disease (COPD), their relationship with the pathogenesis of COPD and how they may affect disease progression. Biomarkers, inclu...

Mar 7th, 2021 - Alpha1-antitrypsin deficiency (AATD) is an inherited condition that predisposes individuals to an increased risk of developing lung and liver disease. Even though AATD is one of the most widespread inherited diseases in Caucasian populations, only...

Oct 28th, 2021 - This study is a multicenter, open-label trial to evaluate the safety and pharmacokinetics of weekly intravenous (IV) infusions of 60 mg/kg of the investigational drug in participants with alpha1-antitrypsin deficiency (AATD). The trial will be con...

Sep 9th, 2014 - The objective of this study is to demonstrate the pharmacokinetic comparability of Alpha-1 MP to Prolastin® in subjects with Alpha1-antitrypsin deficiency. This study is divided into three 8-week treatment sequences including an initial 8-week dou...

May 2nd, 2016 - WASHINGTON, DC — For people who undergo lung transplantation, mortality risk is only slightly higher when donors are 55 to 64 years of age than when they are younger than 55 years, the current age recommendation, according to an analysis of the wo...

May 27th, 2008 - May 27, 2008 — Alpha1-antitrypsin deficiency (AATD) can greatly increase the risk for lung cancer, researchers report. AATD carriers might have a risk of developing lung cancer that is 70% higher than that for noncarriers, according to new data pu...

May 27th, 2008 - May 27, 2008 — Alpha1-antitrypsin deficiency (AATD) can greatly increase the risk for lung cancer, researchers report. AATD carriers might have a risk of developing lung cancer that is 70% higher than that for noncarriers, according to new data pu...